RA2HA
Resimac Premier Series 2020-1
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Cl A3 Frn Mat 07-Feb-2052 Min Cons $5Ht Nc
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in RA2HA
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in RA2HA
N/A
RA2HA investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in RA2HA also invest in...
Want more shares? Try these...
Race Oncology Ltd. is a clinical stage biotechnology company, which engages in the discovery and development of a novel approach to cancer treatment and cardio protection. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. The firm is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart. Its lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. The company is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations. The company is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.
🙌 Performance (5Yr p.a)
129.19%
📊 Share price
$1.38 AUD
🧬 BIOTECHNOLOGY
QYLD.AX was created on 2023-01-30 by Global X. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 8.1m in AUM and 101 holdings. Each Fund aims to provide investors with a return (before fees and other costs) that tracks the performance of the relevant Index.
📊 Share price
$12.23 AUD
🇺🇸 UNITED STATES
🤖 TECHNOLOGY
Regener8 Resources NL engages in raising seed capital to fund the company's activities. The company is headquartered in Perth, Western Australia. The company went IPO on 2022-07-08. The company operates in two segments: the Kookynie Gold Project and the East Ponton Future Metals Project. The Kookynie Gold Project comprises of one exploration license and eight prospecting licenses located in the Kookynie region in Western Australia's Goldfields region. The Kookynie Gold Project is located in the northern Goldfields region of WA, covering an area of approximately 15 square kilometers (km2) within the North Coolgardie Mineral Field. The Project is approximately 155 kilometers (km) north of Kalgoorlie and 55 km south of Leonora Township. Its projects include Niagara West, Niagara East, Niagara North, and the Reach prospect. The East Ponton Future Metals Project consists of the Grasshopper and Seven Sisters prospects located approximately 220 km east of Kalgoorlie, WA. The tenement package is prospective for Rare Earth Elements (REE), Lithium, and Gold.
📊 Share price
$0.15 AUD
⛏️ MINING